

# GLOBAL, CUTTING-EDGE ONCOLOGY CELL & GENE THERAPY CLINICAL TRIAL INTELLIGENCE PLATFORM

- Analyze data and outcomes to design effective trials
- Assess clinical strategies & R&D trends
- Benchmark your asset against emerging data
- Quickly extract data across trial variables including design, tumor indication, target/MoAs, outcomes, competitors, SoC, technology platforms



1750+

Active Oncology  
Clinical Trials

1100+

Heme  
Malignancy Clinical  
Trials

650+

Solid  
Tumors Clinical Trials

250+

Fields  
Analyzed

240+

Indications including  
rare cancers

250+

Corporate Entities

Gain insights on construct designs, engineered platforms, potential biomarkers, emerging targets & treatments, efficacy & safety outcomes

Compare

Explore

Benchmark

Granular

Comprehensive

Dynamic

Most Comprehensive **“Oncology Cell & Gene Therapy”** Clinical Trial Analytics

To talk to our experts and get a demo of the *Cell & Gene Therapy Intelligence Platform*, please [connect with us here](#).



# Tumor Specific Reports

FutureBridge's tumor specific reports provide comprehensive view and foundational data on solid tumors and hematological malignancies. These reports include:

- Disease overview
- Current and emerging segments, treatment practices, standards of care, benchmarks
- Epidemiology
- Competitive landscape of key emerging assets in pipeline, and their estimated launch timelines
- Residual unmet needs
- Target Product Profile to identify opportunity for differentiation

## Unique Features

- ✓ Customizable reports as per client's need
- ✓ Real-time updates by tracking major oncology conferences, trial databases and read-outs, competitors' websites, Company press releases, and milestone data
- ✓ Detailed and in-depth insights into the future oncology landscape and trends
- ✓ Covers geographical nuances of current and emerging landscape

To know more and get a walkthrough of our tumor landscape reports/ share your business objective, please [connect with us here](#).

# Tumor Landscape Report Series



Tumor Specific Concise Reports on Current & Emerging Treatments, Trends & Future Directions

## Tumor/Indication Coverage

### Solid Tumors

#### Lung Cancer

- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Mesothelioma

#### Breast Cancer

- Triple Negative Breast Cancer (TNBC)
- HER2+ Breast Cancer
- HR+ Breast Cancer

#### Genito-urinary Cancer

- Prostate Cancer (PrCa)
- Renal Cancer (RCC)
- Testicular Cancer
- Bladder Cancer

#### Gastro-intestinal Cancer

- Colorectal Cancer (CRC)
- Gastric Cancer
- Esophageal Cancer
- Liver Cancer (HCC)
- Pancreatic Ca (PaCa)
- Anal cancer
- Rectal cancer
- Biliary Cancer

#### Gynaecological Cancer

- Endometrial Cancer
- Cervical Cancer
- Ovarian Cancer (OvCa)

#### Head & Neck Cancer (SCCHN)

#### Thyroid Cancer

#### Melanoma

#### Uveal melanoma

#### Non melanoma skin cancers

- Cutaneous squamous cell carcinoma (CSCC)
- Basal cell carcinoma (BCC)
- Merkel Cell Carcinoma (MCC)

#### Soft Tissue Sarcoma (STS)

#### Neuroendocrine Tumors (NET)

### Hematological Malignancies

#### B-Cell Lymphoma & Leukemia

- Diffuse large B-cell lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Acute Myeloid Leukemia (AML)
- Acute Lymphocytic Leukemia (ALL)
- Marginal Zone Lymphoma (MZL)
- Chronic Lymphocytic Leukemia (CLL)/ Small Small Lymphocytic Lymphoma (SLL)

#### Plasma Cell Disorders

- Multiple Myeloma (MM)

#### B-Cell Lymphoma

- Hodgkin Lymphomas (HL)
- Waldenstrom Macroglobulinemia (WM)

#### Myelodysplastic syndromes (MDS)

#### Mature T-Cell Lymphoma

- Peripheral T cell Lymphoma (PTCL)
- Cutaneous T cell Lymphoma (CTCL)

To know more and get a walkthrough of our tumor landscape reports/ share your business objective, please [connect with us here](#).